Louis Archambault

Prof. Louis Archambault

orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2024 in Physics in Medicine & Biology
Verified
Journal Article
Closed access
MSMojtaba Safari
Mojtaba Safari
Xiaofeng YangXiaofeng Yang
Xiaofeng Yang
CCChih-Wei Chang
Chih-Wei Chang
RQRichard L J Qiu
Richard L J Qiu
AFAli Fatemi
Ali Fatemi
LALouis Archambault
Louis Archambault
Objective. This study developed an unsupervised motion artifact reduction method for magnetic resonance imaging (MRI) images of patients with brain tumors. The proposed novel design uses multi-parametric multicenter contrast-enhanced T1W (ceT1W) and T2-FLAIR MRI images. Approach. The proposed framework included two generators, two discriminators, and two feature extractor networks. A 3-fold cross-validation was used to train and fine-tune the hyperparameters of the proposed model using 230 brain MRI images with tumors, which were then tested on 148 patients’ in-vivo datasets. An ablation was performed to evaluate the model’s compartments. Our model was compared with Pix2pix and CycleGAN. Six evaluation metrics were reported, including normalized mean squared error (NMSE), structural similarity index (SSIM), multi-scale-SSIM (MS-SSIM), peak signal-to-noise ratio (PSNR), visual information fidelity (VIF), and multi-scale gradient magnitude similarity deviation (MS-GMSD). Artifact reduction and consistency of tumor regions, image contrast, and sharpness were evaluated by three evaluators using Likert scales and compared with ANOVA and Tukey’s HSD tests. Main results. On average, our method outperforms comparative models to remove heavy motion artifacts with the lowest NMSE (18.34±5.07%) and MS-GMSD (0.07 ± 0.03) for heavy motion artifact level. Additionally, our method creates motion-free images with the highest SSIM (0.93 ± 0.04), PSNR (30.63 ± 4.96), and VIF (0.45 ± 0.05) values, along with comparable MS-SSIM (0.96 ± 0.31). Similarly, our method outperformed comparative models in removing in-vivo motion artifacts for different distortion levels except for MS- SSIM and VIF, which have comparable performance with CycleGAN. Moreover, our method had a consistent performance for different artifact levels. For the heavy level of motion artifacts, our method got the highest Likert scores of 2.82 ± 0.52, 1.88 ± 0.71, and 1.02 ± 0.14 (p-values ≪ 0.0001) for our method, CycleGAN, and Pix2pix respectively. Similar trends were also found for other motion artifact levels. Significance. Our proposed unsupervised method was demonstrated to reduce motion artifacts from the ceT1W brain images under a multi-parametric framework.

23 May 2020 in Medical Physics
Verified
Journal Article
Closed access
PDF file
MRMadison Rilling
Madison Rilling
GAGuillaume Allain
Guillaume Allain
STSimon Thibault
Simon Thibault
LALouis Archambault
Louis Archambault


8 November 2015 in Journal of Applied Clinical Medical Physics
Verified
Journal Article
Open access
PDF file
ABAlexandra Bourgouin
Alexandra Bourgouin
NVNicolas Varfalvy
Nicolas Varfalvy
LALouis Archambault
Louis Archambault
The objectives of this project are to quantify the dose reduction effect provided by a lead shield for patients with cardiac implantable electronic devices (CIED) during a clinically realistic radiation treatment on phantom and to provide a simple model of dose estimation to predict dose received by CIED in a wide range of situations. The shield used in this project is composed of a lead sheet wrapped in thermoplastic. Dose measurements were made with a plastic scintillation detector (PSD). The phantom was treated with ten different plans. Three of these cases were treated with intensity-modulated radiation therapy (IMRT) and the others received standard 3D conformal radiation therapy (3D CRT). Lateral dose measurement for photon fields was made to establish a dose prediction model. On average, the use of the lead shield reduced the dose to CIEDs by 19%?13% . Dose reduction was most important for breast cases, with a mean reduction of 31%?15% . In three cases, the total dose reduction was more than 25 cGy over the complete treatment. For the three IMRT cases, the mean dose reduction was 11%?9% . On average, the difference between the TPS prediction and the measurement was 71%, while it was only 14% for the dose prediction model. It was demonstrated that a lead shield can be efficiently used for reducing doses to CIED with a wide range of clinical plans. In patients treated with IMRT modality treatment, the shielding should be used only for those with more than two anterior fields over seven fields. In the case of 3D CRT patients, the shielding should be used for those with a dose on the CIED higher than 50 cGy and with a reduction of dose higher than 10 cGy. The dose prediction model developed in this study can be an easy way to have a better estimation of the out-of-field dose than the TPS. PACS number(s): 87.55.N, 87.55.km

7 February 2020 in IEEE Transactions on Games
Verified
Journal Article
Closed access
DGDaniel Gourdeau
Daniel Gourdeau
LALouis Archambault
Louis Archambault

18 September 2017 in Medical Physics
Verified
Journal Article
Closed access
PDF file
NVNicolas Varfalvy
Nicolas Varfalvy
OPOphelie Piron
Ophelie Piron
MCMarc François Cyr
Marc François Cyr
ADAnne Dagnault
Anne Dagnault
LALouis Archambault
Louis Archambault